Sage Therapeutics, Inc. (USD) Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sage Therapeutics, Inc. (USD) Active

215 First Street, Cambridge, MA, US, 02142

Stock Price USD

Price Change

Last Dividend USD

Latest Rating

SAGE's stock peer is AKRO (Akero Therapeutics, Inc.)

SAGE's stock peer is ALNY (Alnylam Pharmaceuticals, Inc.)

SAGE's stock peer is AMLX (Amylyx Pharmaceuticals, Inc.)

SAGE's stock peer is APLS (Apellis Pharmaceuticals, Inc.)

SAGE's stock peer is ARVN (Arvinas, Inc.)

SAGE's stock peer is BDTX (Black Diamond Therapeutics, Inc.)

SAGE's stock peer is BPMC (Blueprint Medicines Corporation)

SAGE's stock peer is CERE (Cerevel Therapeutics Holdings, Inc.)

SAGE's stock peer is DAWN (Day One Biopharmaceuticals, Inc.)

SAGE's stock peer is DMAC (DiaMedica Therapeutics Inc.)

SAGE's stock peer is IMCR (Immunocore Holdings plc)

SAGE's stock peer is INCY (Incyte Corporation)

SAGE's stock peer is KRYS (Krystal Biotech, Inc.)

SAGE's stock peer is MDGL (Madrigal Pharmaceuticals, Inc.)

SAGE's stock peer is MRTX (Mirati Therapeutics, Inc.)

SAGE's stock peer is NUVL (Nuvalent, Inc.)

SAGE's stock peer is PLRX (Pliant Therapeutics, Inc.)

SAGE's stock peer is RETA (Reata Pharmaceuticals, Inc.)

SAGE's stock peer is RLAY (Relay Therapeutics, Inc.)

SAGE's stock peer is STOK (Stoke Therapeutics, Inc.)

SAGE's stock peer is TERN (Terns Pharmaceuticals, Inc.)

SAGE's stock peer is VTYX (Ventyx Biosciences, Inc.)

Healthcare Biotechnology

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

20%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

60%

Debt To Equity

20%

Price To Earnings

80%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sage Therapeutics, Inc. (NASDAQ: SAGE) to Supernus Pharmaceuticals, Inc. is fair to Sage shareholders. Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon achieving certain net sales and commercial milestones. Halper Sadeh encourage.

2025-06-16 09:10:00

Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Sage will receive $8.50 per share in cash (or an aggregate of ap.

2025-06-16 07:38:00

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.

2025-06-15 10:00:00

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.

2025-06-12 10:00:00

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.

2025-06-10 10:00:00

INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. and Encourages Long-Term Investors to Contact the Firm - SAGE

PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage") on behalf of the company's long-term investors. Click here to receive additional information about your legal rights and options: https://kaskelalaw.com/case/sage-therapeutics/ Recently a securities fraud complaint was filed against Sage on behalf of certain investors who purchased or acquired shares of the company's stock between April 12, 2021 and July 23, 2024.

2025-06-09 08:30:00

Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.

2025-06-08 10:00:00

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.

2025-06-05 10:00:00

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.

2025-06-03 10:00:00

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE.

2025-06-01 10:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions